Michael Blankenburg

775 total citations
24 papers, 538 citations indexed

About

Michael Blankenburg is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Blankenburg has authored 24 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Cardiology and Cardiovascular Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Blankenburg's work include Blood Pressure and Hypertension Studies (5 papers), Chronic Kidney Disease and Diabetes (4 papers) and Diabetes Treatment and Management (4 papers). Michael Blankenburg is often cited by papers focused on Blood Pressure and Hypertension Studies (5 papers), Chronic Kidney Disease and Diabetes (4 papers) and Diabetes Treatment and Management (4 papers). Michael Blankenburg collaborates with scholars based in Germany, United States and Ireland. Michael Blankenburg's co-authors include Lisa Bloudek, Sean D. Sullivan, Eldon Spackman, M. Eric Gershwin, Thomas Prindiville, Te‐Chun Hsia, G. M. Halpern, Alain Gay, Csaba P. Kövesdy and Kerstin Folkerts and has published in prestigious journals such as Diabetes, Mayo Clinic Proceedings and Nephrology Dialysis Transplantation.

In The Last Decade

Michael Blankenburg

23 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Blankenburg Germany 10 183 170 83 73 71 24 538
Karen J. Friday United States 15 113 0.6× 151 0.9× 434 5.2× 55 0.8× 13 0.2× 33 2.7k
Mohan Giri China 12 75 0.4× 214 1.3× 163 2.0× 18 0.2× 15 0.2× 42 637
Shun‐Ku Lin Taiwan 16 71 0.4× 73 0.4× 90 1.1× 18 0.2× 35 0.5× 42 599
Pekka Reinikainen Finland 13 21 0.1× 37 0.2× 36 0.4× 11 0.2× 44 0.6× 20 667
Joey S.W. Kwong China 13 34 0.2× 21 0.1× 48 0.6× 38 0.5× 45 0.6× 25 477
Gwo‐Ping Jong Taiwan 15 13 0.1× 51 0.3× 127 1.5× 33 0.5× 214 3.0× 62 747
Steven Shea United States 11 51 0.3× 72 0.4× 29 0.3× 47 0.6× 43 0.6× 15 560
Chern‐En Chiang Taiwan 20 20 0.1× 40 0.2× 288 3.5× 66 0.9× 92 1.3× 55 1.6k

Countries citing papers authored by Michael Blankenburg

Since Specialization
Citations

This map shows the geographic impact of Michael Blankenburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Blankenburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Blankenburg more than expected).

Fields of papers citing papers by Michael Blankenburg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Blankenburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Blankenburg. The network helps show where Michael Blankenburg may publish in the future.

Co-authorship network of co-authors of Michael Blankenburg

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Blankenburg. A scholar is included among the top collaborators of Michael Blankenburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Blankenburg. Michael Blankenburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Endrikat, Jan, et al.. (2025). Rationales for Non-standard GBCA Dosing—Low?—High?—When? and Why?. Investigative Radiology.
2.
Blankenburg, Michael, et al.. (2024). Unlocking the Value: Quantifying the Return on Investment of Hospital Artificial Intelligence. Journal of the American College of Radiology. 21(10). 1677–1685. 18 indexed citations
3.
4.
5.
Subramanian, Dhinagar, et al.. (2023). To pay or not to pay for artificial intelligence applications in radiology. npj Digital Medicine. 6(1). 117–117. 25 indexed citations
6.
7.
Blankenburg, Michael, et al.. (2022). Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA. Journal of Medical Economics. 25(1). 1015–1029. 3 indexed citations
8.
Folkerts, Kerstin, Natalia Petruski‐Ivleva, Michael Blankenburg, et al.. (2021). Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database. Mayo Clinic Proceedings. 96(4). 975–986. 37 indexed citations
9.
Folkerts, Kerstin, Natalia Petruski‐Ivleva, Linda F. Fried, et al.. (2021). Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study. ˜The œNephron journals/Nephron journals. 145(4). 342–352. 6 indexed citations
10.
Kövesdy, Csaba P., Natalia Petruski‐Ivleva, Linda F. Fried, et al.. (2020). Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. Clinical Kidney Journal. 14(6). 1657–1664. 18 indexed citations
11.
12.
Folkerts, Kerstin, Natalia Petruski‐Ivleva, Linda F. Fried, et al.. (2020). Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. Journal of Managed Care & Specialty Pharmacy. 26(12). 1506–1516. 35 indexed citations
13.
14.
15.
16.
Blankenburg, Michael, et al.. (2015). Patient Benefits And Cost Savings Predicted For Mineralocorticoid-Receptor Antagonist Treatment Of Early And Advanced Diabetic Kidney Disease. Value in Health. 18(7). A508–A508. 2 indexed citations
17.
18.
Schipke, Carola G., Oliver Peters, Isabella Heuser, et al.. (2012). Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 33(6). 416–422. 54 indexed citations
19.
Calvó‐Perxas, Laia, Secundino López‐Pousa, Joan Vilalta‐Franch, et al.. (2012). Central Nervous System Drug Consumption Depending on the Time between Symptom Onset and the Diagnosis of Alzheimer’s Disease: An Analysis by the Registry of Dementias of Girona. Dementia and Geriatric Cognitive Disorders. 33(2-3). 104–110. 5 indexed citations
20.
Blankenburg, Michael, et al.. (2011). PMD51 Cost Savings and Improved Utility through the Use of Florbetaben Beta-Amyloid PET Imaging in Dementia Diagnosis. Value in Health. 14(7). A253–A253. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen J. Friday Breakdown of academic impact, for papers by Mohan Giri Breakdown of academic impact, for papers by Shun‐Ku Lin Breakdown of academic impact, for papers by Pekka Reinikainen Breakdown of academic impact, for papers by Joey S.W. Kwong Breakdown of academic impact, for papers by Gwo‐Ping Jong Breakdown of academic impact, for papers by Steven Shea Breakdown of academic impact, for papers by Chern‐En Chiang
Rankless by CCL
2026